R. Gonzalez

BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with <i>BRAF</i> V600E mutation-positive metastatic melanoma.

A. Ribas, K. B. Kim, Lynn M. Schuchter et al. · Journal of Clinical Oncology · 2011 · 131 citations

Mutant Braf, Skin Cancer, Braf Gene +9

Immunotherapy of Advanced Malignancy by Direct Gene Transfer of an Interleukin-2 DNA/DMRIE/DOPE Lipid Complex: Phase I/II Experience

Evanthia Galanis, E. M. Hersh, Alison Stopeck et al. · Journal of Clinical Oncology · 1999 · 99 citations

A phase II, randomized, open-label study evaluating the antitumor activity of MEDI-522, a humanized monoclonal antibody directed against the human alpha v beta 3 (avb3) integrin, ± dacarbazine (DTIC) in patients with metastatic melanoma (MM)

Peter Hersey, Jeff Sosman, Steven O’Day et al. · Journal of Clinical Oncology · 2005 · 55 citations

Immunology, Immunotherapeutics, Immunotherapy +17

Treatment of patients with metastatic melanoma with bryostatin-1 - phase II study

R. Gonzalez, S. Ebbinghaus, T. K. Henthorn et al. · Melanoma Research · 1999 · 45 citations

3303 Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067)

James Larkin, Vanna Chiarion‐Sileni, R. Gonzalez et al. · European Journal of Cancer · 2015 · 36 citations

Oncology, Key Patient Subgroups, Melanoma +7